Bristol-Myers Squibb CompanyBMY

BMY current price
$59.82+25.30%

Capital at risk.

1W
+8.39%
1M
+14.97%
3M
+23.29%
6M
+37.36%
1Y
+25.30%
MAX
+39.73%
Calendar
event
Ex dividend date
04 Oct 2024
event_available
Last Dividend Payment
01 Nov 2024
About Bristol-Myers Squibb Company
Ticker
info
BMY
Trading on
info
NYSE
ISIN
info
US1101221083
Industry
info
Drug Manufacturers - General
Sector
info
Healthcare
CEO
info
Dr. Christopher S. Boerner Ph.D.
Headquarters
info
Route 206 & Province Line Road, Princeton, NJ, United States, 08543
Employees
info
34,100
Website
info
bms.com
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Metrics
BasicAdvanced
Market cap
info
$121B
P/E ratio
info
-
EPS
info
-$3.58
Dividend Yield
info
4.43%
Beta
info
0.44
Forward P/E ratio
info
7.76
EBIDTA
info
$19.2B
Ex dividend date
info
2024-10-04
Price & volume
Market cap
info
$121B
Average daily volume
info
10.1M
90-day return
info
23.29%
30-day return
info
14.97%
7-day return
info
8.39%
Dividends
Dividend per share
info
$2.40
Dividend yield
info
4.43%
Forward dividend per share
info
$2.40
Forward dividend yield
info
4.43%
Payout ratio
info
2.26%
Valuation
P/E ratio
info
0
Forward P/E
info
7.76
PEG ratio
info
1.99
Trailing P/E
info
0
Price to sales
info
2.56
Price to book
info
6.41
Earnings
EPS
info
-$3.58
EPS estimate (current quarter)
info
$1.49
EPS estimate (next quarter)
info
$1.52
EBITDA
info
$19.2B
Revenues (TTM)
info
$47.4B
Revenues per share (TTM)
info
$23.41
Technicals
Beta
info
0.44
52-week High
info
$61.08
52-week Low
info
$38.60
50-day moving average
info
$51.87
200-day moving average
info
$48.07
Short ratio
info
1.75
Short %
info
1.11%
Management effectiveness
ROE (TTM)
info
31.33%
ROA (TTM)
info
6.07%
Profit margin
info
15.30%
Gross profit margin
info
$36.4B
Operating margin
info
18.48%
Growth
Quarterly earnings growth (YoY)
info
35.80%
Quarterly revenue growth (YoY)
info
8.40%
Share stats
Outstanding Shares
info
2.03B
Float
info
2.02B
Insiders %
info
0.11%
Institutions %
info
78.13%
Analyst Insights & forecasts
info

20% Buy

72% Hold

8% Sell

Based on information from 25 analysts.

Average price target

info
$53.53
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$1.59
$1.43
11.19%
Q4 • 23Beat
-$4.40
-$4.14
6.28%
Q1 • 24Beat
$2.07
$1.63
26.99%
Q2 • 24Beat
$1.80
$1.49
20.81%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$12.2B
$1.68B
13.77%
Q2 • 24
$11.9B
$1.21B
10.18%
Q3 • 24
2.53%
27.92%
26.04%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$94.6B
$77.6B
81.97%
Q2 • 24
$93.7B
$76.5B
81.64%
Q3 • 24
1.03%
1.43%
0.40%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$2.33B
$-1.32B
$-4.02B
$2.06B
Q2 • 24
$5.59B
$-219M
$-3.85B
$5.27B
Q3 • 24
140.37%
83.40%
4.25%
155.18%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.75

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Bristol-Myers Squibb Company share?
Collapse

Bristol-Myers Squibb Company shares are currently traded for $59.82 per share.

How many shares does Bristol-Myers Squibb Company have?
Collapse

Bristol-Myers Squibb Company currently has 2.03B shares.

Does Bristol-Myers Squibb Company pay dividends?
Collapse

Yes, Bristol-Myers Squibb Company does pay dividends.

What is Bristol-Myers Squibb Company 52 week high?
Collapse

Bristol-Myers Squibb Company 52 week high is $61.08.

What is Bristol-Myers Squibb Company 52 week low?
Collapse

Bristol-Myers Squibb Company 52 week low is $38.60.

What is the 200-day moving average of Bristol-Myers Squibb Company?
Collapse

Bristol-Myers Squibb Company 200-day moving average is $48.07.

Who is Bristol-Myers Squibb Company CEO?
Collapse

The CEO of Bristol-Myers Squibb Company is Dr. Christopher S. Boerner Ph.D..

How many employees Bristol-Myers Squibb Company has?
Collapse

Bristol-Myers Squibb Company has 34,100 employees.

What is the market cap of Bristol-Myers Squibb Company?
Collapse

The market cap of Bristol-Myers Squibb Company is $121B.

What is the P/E of Bristol-Myers Squibb Company?
Collapse

The current P/E of Bristol-Myers Squibb Company is null.

What is the EPS of Bristol-Myers Squibb Company?
Collapse

The EPS of Bristol-Myers Squibb Company is -$3.58.

What is the PEG Ratio of Bristol-Myers Squibb Company?
Collapse

The PEG Ration of Bristol-Myers Squibb Company is 1.99.

What do analysts say about Bristol-Myers Squibb Company?
Collapse

According to the analysts Bristol-Myers Squibb Company is considered a hold.